Physician profile
Wei Bai
NPI 1053567545
$58,600.16
in general payments reported to CMS, 2019-2025
41 companies · $8,225 in 2025
The $8,225 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $232 · 2021: $46.96 · 2022: $4,558 · 2023: $28K · 2024: $17K · 2025: $8,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $16K · Travel and Lodging: $2,585 · Food and Beverage: $1,946 · Honoraria: $200 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,075.00 |
| Consulting Fee | $15,910.00 |
| Travel and Lodging | $2,585.16 |
| Food and Beverage | $1,946.27 |
| Honoraria | $200.00 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41,545.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $7,941.32 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Sanofi-Aventis U.S. LLC | $2,970.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $1,654.88 | 2019-2023 | Piqray |
| Incyte Corporation | $1,113.72 | 2019-2025 | |
| Astellas Pharma US INC | $468.24 | 2022-2025 | Padcev, Xospata, Vyloy |
| Janssen Biotech, INC. | $330.26 | 2019-2024 | Rybrevant |
| Lilly USA, LLC | $241.87 | 2019-2023 | Verzenio |
| E.R. Squibb & Sons, L.L.C. | $234.05 | 2020-2025 | Onureg |
| Daiichi Sankyo INC. | $229.77 | 2021-2025 | Datroway |
| Merck Sharp & Dohme LLC | $178.81 | 2019-2023 | Lynparza, Keytruda |
| Exelixis INC. | $173.21 | 2019-2025 | Cabometyx |
| Atricure, INC. | $159.94 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Pfizer INC. | $125.21 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $124.99 | 2022 |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Bai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.